Daxor Announces that Hartford Hospital of Hartford, CT Acquires BVA-100 Blood Volume Analyzer

Daxor Corporation

, a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from Hartford Hospital of Hartford, Connecticut. This will provide Hartford Hospital with a Blood Volume Analyzer-100 (BVA-100), an instrument which enables semi-automated measurement of a patient's total blood volume, red blood cell volume and plasma volume. Blood volume abnormalities are observed in a variety of cardiac conditions and have been associated with poor prognosis. Hartford Hospital will be participating in a multi-center clinical trial (TEAM-HF) which will test whether incorporation of blood volume assessments into treatment decisions can improve the care and outcomes of patients with heart failure. Dr. Detlef Wencker, director of the heart failure and transplant center, will serve as the local Principal Investigator, and will be joined by Drs. Joseph Radojevic and Jason A. Gluck to conduct the study at Hartford Hospital. The objective of the interventional TEAM-HF Study is to determine whether correcting any identified blood volume abnormalities in heart failure patients leads to decreased hospitalization and mortality, and an improvement in exercise capacity and quality of life. This trial will enroll 300 heart failure patients from 11 medical centers.